ANNUAL REPORT

2022

ASID AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES

Our Annual Report

We are the peak professional body for infectious diseases and microbiology in Australasia and a key stakeholder for government departments, medical colleges and other societies, including international organisations. Our members include Infectious Diseases Physicians, Clinical Microbiologists, Scientists, Infection Control Practitioners, Public Health Physicians, Sexual Health Physicians, Veterinarians and others eminent in the field of infectious diseases.

ASID aims to:

- Advance postgraduate education in infectious diseases in Australasia and internationally;
- Promote research in all aspects of infectious diseases; and
- Advocate for sound and evidence-based public health policy in matters related to infectious diseases.

This Annual Report provides a summary of our activities and performance for the financial year ended 31 December 2022.

The 'old' ASID brand was used for the last time at the 2022 ASM.

Table of Contents

ASID Board

The ASID Board

President
Professor Katie Flanagan
FRACP

Past President
Professor Allen Cheng
FRACP

Finance Committee Chair
Associate Professor
Joseph Doyle
FRACP FAFPHM

Associate Professor
Julia Clark
FRACP

Professor
Rhonda Stuart
FRACP

Professor
David Paterson
FRACP FRCPA

Professor
Chris Blyth
FRACP FRCPA

The ASID Board features some of Australia's most distinguished experts in infectious diseases.

The ASID Council

The directors, the SIG Chairs and other representatives are part of the Council that provides strategic input to the Board.

Dr Nigel Raymond, FRACP (New Zealand representative)

Dr Duncan Campbell (Advanced Trainee representative)

Dr Brendan McMullan (ANZPID Chair)

Dr Celia Cooper, FRACP (ANZMIG Co Chair)

Dr Andrew Stewardson FRACP (HICSIG Chair)

Prof Monica Slavin (ICHSIG Chair)

Prof Fiona Russell (VACSIG Chair)

Dr Jane Davies, FRACP (VHSIG Chair)

Dr Kathryn Wilks (ZOOSIG Co-Chair)
Dr Katrina Bosward (ZOOSIG Co-Chair)

Prof Steven Tong, FRACP (Clinical Research Network Chair)

Dr Jenny Robson, FRCPA (RCPA representative)

Prof Monica Slavin, FRACP (JSAC Chair)

Prof Geoff Coombs (ASA President)

President's Report

This year marked a return to at least some form of face-to-face events for ASID. After almost three years since our lives changed with the emergence of COVID-19, I'm sure all members will agree it was refreshing to get out from behind the computer.

ASID President Professor Katie Flanagan
FRACP

A highlight of the year was the hybrid ASM held in Perth. Thank you to Dr Claire Italiano, Dr Ed Raby & the organising committee for putting on such a wonderful event. It was exciting to finally catch up in person!

The INTREPID program for trainees continued (well done to Duncan Campbell and the team for the excellent series of fortnightly webinars), and ANZPID and ANZMIG met face-to-face for their clinical meetings. ASIDs new SIG, the Immunocompromised Host Special Interest Group (ICHSIG) also convened this year.

The NZ Annual Meeting also returned to normal, meeting in Christchurch in October. Well done to Sarah Metcalf and the local organising committee.

2022 was a year of firsts.

ASID now has 1181 members and for the first time, we have more female members than male.

ASID's new Advocacy and Policy Committee and Equity and Diversity Committee commenced operation so expect to hear more from them in 2023.

In June, the Board was delighted to present ASID's new brand and visual identity. Drawing on the position statement *ASID advances the prevention and treatment of infectious diseases, enhancing the lives of everyone, now and into the future* our new identity has a much more contemporary feel to it, reflecting the importance of our work in 2022 and beyond.

We also launched our new public website which showcases our work to the public in a much more modern and streamlined way. The branding is now used across all our SIG logos, event and webinar collateral, and all other public ASID imagery.

President's Report

You may have also noticed that *The Weekly Dose*, your weekly newsletter delivered to your inbox, has a new look and feel and is full of relevant content. It has an open rate of more than 55% which is testament to how engaged ASID members are. In addition, we have increased our followers on Twitter, Facebook, and LinkedIn.

In 2022, ASID released a number of position statements. ANZPID and VACSIG have been particularly active in public discussions around vaccination policy.

The work of our NZ Sub Committee has been particularly important this year. NZ members hold positions on national advisory groups, advising the PM and cabinet, are involved in Trans Tasman research initiatives and participate in the Vaccine Alliance Aotearoa. Of note, they have been heavily involved in the new *Pae Ora (Healthy Futures) Bill*.

Congratulations to all 2022 ASID Award recipients.

You can read more about the 2022 events, SIGs, and award recipients further on in this report.

We held eight Board Meetings during 2022. I am thankful to work with such a talented group of office bearers. In May we announced that Dr Brendan McMullan and A/Prof Joe Doyle would complete their term of office at the June AGM. While they were both eligible for renomination, Brendan indicated that he would step off the Board. Following a call for nominations in June, we welcomed Dr Chris Blyth to the ASID Board. He has already made a significant contribution to the Board.

President's Report

I would like to thank the ASID Office (Helen, Lara, Serena and Alison) for managing the secretariat, events & webinars, member services, and media and communications.

I would also like to thank all ASID members. The last few years have been challenging, and many members continue to play key roles in the post-COVID environment.

You should be proud of your efforts.

Professor Katie Flanagan
President ASID

New brand

ASID AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES

This year we rebranded our visual identity and redesigned the ASID public website.

We updated our logo to reflect ASID as a positive, progressive and contemporary brand, drawing upon the positioning statement *ASID advances the prevention and treatment of infectious diseases, enhancing the lives of everyone, now and into the future.*

Thank you to the many members who gave us their ideas via surveys and interviews; and to OxBrand Consultants who helped drive the rebranding following a competitive tender process.

The new brand design appears on all our digital channels and marketing collateral.

New public website

We unveiled the new ASID public website in October 2022. Further work commenced on the new Members Only space for ASID Members. The new Circle platform will allow information to be better shared between members.



Special Interest Groups

ASID ANZPID
THE AUSTRALIAN AND NEW ZEALAND PAEDIATRIC INFECTIOUS DISEASES GROUP

Chair: Dr Brendan McMullan
Deputy Chair: Dr Anita Campbell
Members: Dr Archana Koirala, Dr Nan Vasilunas, Dr Rachel Webb
Trainee Committee Member: Michelle Mahoney
ASID Clinical Research Network Committee Member: Dr Ameneh Khatami
The World Society for Pediatric Infectious Diseases (**WSPID**) **member:** Dr Phoebe Williams, Dr Linny Phuong.

ASID ANZMIG
THE AUSTRALIAN AND NEW ZEALAND MYCOSES INTEREST GROUP

Co-Chairs: Dr Celia Cooper and Dr Caitlin Keighley
Immediate past Co-Chair: Assoc Prof Karina Kennedy
Secretary: Dr Sarah Kidd
Scientific Chair: Dr Lucy Crawford
Working Group Chairs: Prof Monica Slavin and Assoc Prof Sharon Chen
Trainee Representative: Dr Max Kernich
Clinical Lead: Dr Abby Douglas
Laboratory Lead: Dr Catriona Halliday

ASID CRN
CLINICAL RESEARCH NETWORK

Chair: Prof Steven Tong
Deputy Chair: Assoc Prof Asha Bowen
Members: Dr Ameneh Khatami, Assoc Prof Joe Doyle, Dr J Hanson, Dr S Morpeth, Dr J Lau, Assoc Prof Gail Matthews, Assoc Prof Jason Trubiano

ASID HICSIG
THE HEALTHCARE INFECTION CONTROL SPECIAL INTEREST GROUP

Chair: Dr Andie Lee
Immediate Previous Chair: Dr Andrew Stewardson
Members: A/Prof Caroline Marshall, Dr Rebecca McCann, Assoc Prof Deb Friedman, Dr Trish Ferguson, Dr Paul Griffin, Dr Jason Kwong, Dr Kate McCarthy, Dr Sally Roberts

Special Interest Groups

ASID ICHSIG THE IMMUNOCOMPROMISED HOST SPECIAL INTEREST GROUP

Chair: Prof Monica Slavin
Deputy Chair: Dr Ben Teh
Members: Assoc Prof Julia Clark, Dr Adam Stewart, Dr Matt Roberts, Dr Peter Boan, Dr Louise Cooley, Dr Tina Marinelli

ASID VACSIG VACCINATION SPECIAL INTEREST GROUP

Committee Chair: Prof Fiona Russell
Deputy Chair: Dr Archana Koirala
Members: Prof Katie Flanagan, Prof Michelle Giles, Assoc Prof Nigel Crawford, Dr Emma Best, Dr Sophie Wen, Dr Ben Teh, Dr Margie Danchin, Dr Phillipa Edmiston.

ASID VH²SIG VIRAL HEPATITIS AND HIV SPECIAL INTEREST GROUP

Chair: Assoc Prof Jane Davies
Deputy Chair: Dr Sushena Krishnaswamy
Members: Assoc Prof Joe Doyle, Prof Jenny Hoy, Prof Gail Matthews, Dr Katerina Lagios, Dr Ali Trad, Dr Sami Stewart
Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) Representative: Phoebe Schroder
Trainee Representative: Dr Naomi Whyler

ASID ZOOSIG THE ZOONOSES SPECIAL INTEREST GROUP

Co-Chairs: Dr Kathryn Wilks and Assoc Prof Katrina Bosward
Members: Assoc Prof Bridget Barber, Dr Richard Bradbury, Prof Bart Currie, Assoc Prof Thomas Gottlieb, Assoc Prof Jane Heller, Dr Richard Malik, Dr Stephen Muhi, Dr Jenny Robson, Dr Harsha Sheorey, Dr Andrew Stewardson
Trainee member: Dr Jane Dyer

Special Interest Groups - Highlights

PUBLICATIONS

A number of ANZPID members worked on the ASID funded publication *Management of Perinatal Infections. Third Edition. November 2022. Editors: Pamela Palasanthiran, Mike Starr, Cheryl Jones and Michelle Giles.* The document has been widely downloaded from the ASID website.

The ANZPID Journal Club continued with VACSIG also commencing a similar process.



CAMPAIGNS

ANZPID provided a submission to The House of Representatives' Standing Committee on Health, Aged Care and Sport who are undertaking an *Inquiry into Long COVID and Repeated COVID Infections.*

ANZPID supported the *RACP Kids Covid Catch Up Campaign*, where .Australia's leading paediatricians, specialist physicians and trainee doctors came together to call for a COVID recovery plan for kids and young people across the country.

ASID Board Member and Past Chair of the Viral Hepatitis and HIV Special Interest Group Assoc Prof Joseph Doyle attended the World Hepatitis Day parliamentary roundtable in July, supporting the *Elimination of hepatitis B and hepatitis C by 2030* campaign.



WEBINARS

Several webinars were held by SIGs to both ASID members and a wider audience. Of note:

VACSIG webinar: *COVID vaccine in children 6 months to 5 years, with an update on safety and effectiveness in all paediatric age groups*

VACSIG Webinar: *Monkeypox & smallpox vaccines: an Australian perspective*. Featured Prof Michael Kidd AM.

ANZPID held a series of three Perinatal Webinars which were highly popular.

ANZMIG held their annual Education Program featuring case presentations and group discussion.

Committees

Co-Chairs: Prof David Paterson and Prof Rhonda Stuart
Members: Prof Margie Danchin, Dr Nila Dharan, Prof Lindsay Grayson, Dr Candice Holland, Dr Nigel Raymond, Prof Fiona Russell, Dr Phoebe Williams, Dr Trent Yarwood

The new committee finalised its Terms of Reference, list of spokespeople, and discussed potential Advocacy items for 2023.

Chair: Assoc Prof Julia Clark
Members: Dr Nadia Chaves, Prof Stephen Kent, Dr Rekha Pai Mangalore, Dr Emily Woolnough

The new committee finalised its Terms of Reference, and discussed how membership data can be best analysed to address equity and diversity issues.

Chair: Dr Nigel Raymond
Treasurer: Dr Arthur Morris
Webmaster/NZBUG Moderator: Dr Richard Everts
Members: Dr Rachel Webb, Dr Sarah Metcalf, Dr Kerry Read, Dr Kate Grimwade, Dr Susan Morpeth, Dr Aliya Bryce, Dr Juliet Elvy.
Trainee Representative: Michael-John Fay

The ASID NZ Sub Committee has worked hard to develop an Infection Services document for the Interim Health Plan, as part of the *Pae Ora (Healthy Futures) Bill* which aims to create Health New Zealand and a Maori Health Authority with a joint Board, and a new Public Health Agency as a business unit within the Ministry of Health. Member have also provided input to the new NZ Infectious Diseases research platform.

Outgoing ASID President Professor Allen Cheng opens the ASM in Perth June 2022.

Events & Meetings

ASM 2022

Thank you to all local & international speakers, delegates, Dr Claire Italiano, Dr Ed Raby & the organising committee for putting on a wonderful ASM in Perth in June 2022. Over 400 delegates made the event *Papers to pearls: converting research to everyday practice* a great success.

Thank you to our Platinum Sponsor - MSD, Gold Sponsor and Coffee Cart Sponsor - PFIZER, Gold Sponsor - Gilead, Silver Sponsor - AstraZeneca, Technology Sponsor - GSK, Trainee Breakfast Sponsor - Moderna.

In addition, after more than two years of online learning, INTREPID brought everyone together at the ASM for some much needed networking, socialising and learning in Perth.

MacFarlane Burnet Oration

We were proud to welcome Professor Gagandeep Kang, Professor of Microbiology, at the Wellcome Trust Research Laboratory, Division of Gastrointestinal Sciences at the Christian Medical College (CMC) in Vellore. She spoke on *The infectious disease iceberg: Measuring disease, making policy in India.*

Events & Meetings

ASID NZ Annual Meeting 2022

Thank you to the more than 55 attendees who attended the NZ Annual Meeting in Christchurch in Oct 2022.
Sarah Metcalf and the local organising committee delivered a most engaging and relevant program
Thank you to our Gold Sponsor - Pfizer, Bronze Sponsor - AstraZeneca, and Blue Sponsor - MSD.

Left: This is what the new Christchurch Cathedral, devastated in the 22 February 2011 earthquake, will look like when it is restored. Photo: Otago Daily Times.

Many SIGS held clinical meetings throughout the year.

Left: Welcome to Country at the November 2022 ANZPID Clinical Meeting in Adelaide.

INTREPID

The **IN**troductory **TR**ainee **Ed**ucation **P**rogram in **I**nfectious **D**iseases continued this year with monthly webinars. Well done to Duncan Campbell and the team for creating such an engaging program.

ASID INTREPID
INTRODUCTORY TRAINEE EDUCATION PROGRAM IN INFECTIOUS DISEASES

2022 Award Recipients

Frank Fenner Award for Advanced Research in Infectious Diseases

Congratulations to Associate Professor Asha Bowen (accepting her award from President Professor Allen Cheng at the Perth ASM). *Curiosity is the essence of science* she said in accepting the award.

2022 ASID AWARD WINNERS

ASID Research Grant ($25,000): Dr Olivia Smibert
Council Scholarship: Dr Ella Meumann
Advanced Trainee Research Award: Dr Li Jun Thean
John Forbes Developing Nations Travelling Scholarship: Dr Helio Sarmento Freitas Guterres
Best Poster Award: Dr Hayden Zhang
Best ePoster Award: Dr Trisari Lestari
Australian & New Zealand Mycoses SIG Award: Dr Caitlyn Sun
Australian & New Zealand Paediatric Infectious Diseases SIG Award: Dr Li Jun Thean
Infection Control and Antimicrobial Stewardship Award: Dr Andrew Fox-Lewis
Viral Hepatitis SIG Award: Dr Matthew Pitman
Vaccination SIG Award: Dr Celia Gusmao & Dr Anne Hoey
Barrie Marmion ZOOSIG Award: Dr Rosie Matthews

LIFE MEMBER

Congratulations to
Prof Cheryl Jones
ASID President 2015-2018

Advocacy

ASID released the following statements in 2022. These are available on the ASID website.

8/12/22: *ANZPID Submission: Inquiry into Long COVID and Repeated COVID Infections*

26/8/22: *Viral Hepatitis Special Interest Group supports national response to eliminate hepatitis B and hepatitis C by 2030 28 July 2022*

26/8/22: *ASID Special Interest Groups support ATAGI advice on COVID-19 vaccinations for children aged 6 months to <5 years old in Australia.*

1/7/22: *All children over six months of age should get the influenza vaccine: Australian and New Zealand Paediatric Infectious Diseases Group*

30/6/22: *Vaccination Special Interest Group supports ATAGI recommendations*

24/6/22: *ASID welcomes the Australian Government's commitment to establish a national Centre for Disease Control in Australia*

18/6/22: *Leading Western Australian paediatric infectious diseases specialist honoured with Frank Fenner Award*

11/1/22: *The Australian and New Zealand Paediatric Infectious Diseases Group (ANZPID) supports efforts to prioritise access to education for children and young people.*

Secretary's Report

Associate Professor Julia Clark
FRACP

I would like to welcome all new Full and Associate ASID Members who joined ASID during 2022, and to thank all our ongoing Members for their continued support.

As at 31 Dec 2022 ASID membership grew to **1181** members comprising:

- **Full:** 627
- **Associate:** 489
- **Retired:** 30
- **Honorary:** 35

Below is data on our members. For the first time in ASID history, we have more female members than male.

Please see APPPENDIX for New Associate Members, New Full Members and Members admitted to FRACP.

Membership by location



Membership by gender



Treasurer's Report

ASID's financial performance during 2022 has once again been very steady, even though a slight loss was incurred. This year saw capital spend on the new public website which was developed with minimal spend.

See the Audited Accounts at the end of this Report.

Associate Professor Joseph Doyle
FRACP
FAFPHM

Membership fees	**2022**	**2023**
Assoc AUS	$125	$129
Assoc MIC	$40	$41
Assoc NZ/OS	$105	$109
Full AUS	$330	$342
Full NZ/OS	$290	$300
Life	Comp	Comp
Retired AUS	$35	$36
Retired NZ/OS	$30	$31

As outlined in last years Annual Report annual subscriptions rose in 2023 (noting that we have not had a rise in memberships rates for the last couple of years and underlying costs have increased with CPI).

Appendix

New Associate Members 2022

NSW

Name	Referees
Helen Baxter	Pam Konecny & Robert Stevens
Samiha Rifaath Anver	Archana Sud & Michael Findlay
Tanya Sinha	Elaine Cheong & Timothy Gray
Annalise Unsworth	Eunice Liu & Shelanah Fernando
Romeo Torres	Steve Krilis & Pam Konecny
Baotuti Sebolao	Michael Findlay & Archana Sud
Natalie Beylis	William Rawlinson & Robert Stevens
Roselle Robosa	Jeremy Brown & Debbie Marriott
Cassandra Doig	Sudharsan Venkatesan & Eunice Liu
Vivian Giang	Adam Bartlett & Brendan McMullan
William Duggan	Parastou Valeh & Sarah Coghill
Jessica Bui	Debbie Marriot & Jeremy Brown
Charbel Wehbe	Adrian Ong & Ravindra Dotel
Jung (Jenny) Yeun Park	Indy Sandaradura & Ravindra Dotel

NZ

Name	Referees
Da-Kyung Lee	Matthew Kelly & Nigel Raymond
Emma Henderson	Juliet Elvy & Tim Blackmore
Andrea Peat	Max Bloomfield & Olivia Bupha-Intr
Imogen Nolan	Stephen McBride & Susan Morpeth
Natasha Pool	Genevieve Walls & Christopher Luey
Amelia Shin	Kerry Read & Hasan Bhally

QLD

Name	Referees
Arianne Blanco	Chris Heather & Kimberly Oman
Neetu Shrivastava	Sally Appleton & Vichitra Sukumaran
Samantha Stowasser	Krispin Hajkowicz & Paul Chapman
Rosie Matthews	Jim Stewart & Simon Smith
Keith Hall	David Looke & Lana Sundac

Appendix

New Associate Members 2022 (cont'd)

QLD (cont'd)

Name	Referees
Zack Klyza	Lana Sundac & Marjoree Sehu
Cody Price	Jim Stewart & Simon Smith
Hanna Grimson	Lana Sunac & Alexandra Stewart
Janine Carrucan	Carly Hughes & Christopher Heather
Drew Farquhar	Thi Aung & Shradha Subedi
Sophie Cunningham	Robert Norton & Carly Hughes
Debora Kidanu	Kylie Alcorn & Andrew Jones
Amy Legg	Sonja Jansen & Joshua Davis

SA

Name	Referees
Frank Zhang	Kelly Papanaoum & David Gordon
Helena Torpy	Emily Rowe & Morgyn Waner
Vijia Sivanasan	Rory Hannah & Oui Ju
Christopher Wong	Anushia Ashokan & Emily Rowe

TAS

Name	Referees
Kate Tasker	Katie Flanagan & Jenny O'Hern

VIC

Name	Referees
Rachel Heenan	Deb Friedman & Suman Majumdar
Namraj Goire	Linda Dreyer & Lynette Waring
Genevieve Martin	Kate Cherry & Justin Denholm
Chin Fen Neoh	Monical Slavin & Sharon Chen
Bryan Tan	Sushena Krishnaswamy & Sabien De Silva
Jasmine Choi	Steve Guy & Thomas Schulz
Neta Patersiel	Steven Tong & Joshua Davis
Mei Jie Tang	Andrew Stewardson & Catherine Cherry
Leong Shuen Loo	Roy Chean & Stephen Guy

Appendix

VIC

Name	Referees
Nimna Gamage	Claire Dendle & Ian Woolley
Jordan Kahn	Natasha Holmes & Saliya Hewagama
Hugh Murray	Eugene Athan & Justin Denholm
Beth Morgan	Ian Woolley & Claire Dendle
Gabriel Paykin	Abby Douglas & Natasha Holmes
Paoloa Villanueva	Penelope Bryant & Mike Starr
Ashmitha Thomas	Andrew Mahony & Sarah Garner
Benjamin Aw-Yeong	Doug Johnson & Ian Jennings
Yoko Asakawa	Linny Phuong & Joshua Osowicki
Robert Stolz	Amy Crowe & Steve Muhi
Georgia Walker	Jeremy Carr & Mike Star
Melinda Suchard	Deb Williamson & Linder Dreyer
Ranjit Samra	Christopher Fairley & Christian McGrath
Heather Weerdenburg	Amanda Gwee & Joshua Osowicki
Jack Cornish	Callum Maggs & Andrew Hughes

WA

Name	Referees
Fionnuala Murray	Claire Italiano & Ed Raby
Sarah Cole	Julie Hart & Eric Chu
Rebecca Long	Peter Boan & Thel Hla
Luke Willis	Thel Hla & Arindam Chakravorty
Raena Kaur	Peter Boan & Paul Ingram
Robert Holden	Claire Italiano & Katherine Norton
Maryam Sherkat Masoum	Katherine Norton & Claire Italiano
Jacky Luu	Penelope Clohessy & Thomas Gliddon

Appendix

New Full Members 2022

ACT

Name	Proposed/Seconded
Sam Hamilton	Jane Heller & Brendan McMullan

CAMBODIA

Name	Proposed/Seconded
Vanina Guernier	David Looke & Stephen Graves

NSW

Name	Proposed/Seconded
Kataki Sharma	Archana Koirala & Kristine Macartney

NZ

Name	Proposed/Seconded
Ranmini Kularatne	Max Bloomfield & Matthew Blakiston

QLD

Name	Proposed/Seconded
Anna Maria Peri	David Paterson & Patrick Harris

UK

Name	Proposed/Seconded
Hector Maxwell-Scott	Shobini Sivagnanam & Sharon Chen

VIC

Name	Proposed/Seconded
Norelle Sherry	Natasha Holmes & Andrew Mahony
Sarah Wong	Joanna Chua & Dorothy Ling

Appendix

New LMIC Members 2022

CAMBODIA

Name	Proposed/Seconded
Mona Kheng	Deborah Tong & John Ferguson

INDIA

Name	Proposed/Seconded
Nabaneeta Dash	David Looke & Stephen Graves

SRI LANKA

Name	Proposed/Seconded
Chandika Gamage	Katie Flanagan & Brendan McMullan

VIETNAM

Name	Proposed/Seconded
Kim Van Nguyen	Eugene Athan & Stephanie Jones

Members admitted to FRACP since 2022 AGM

Name	State
Bryant Koh	NSW
Kimberly Cipko	NSW
Candice Holland	QLD
Carly Hughes	QLD
Susan Harch	SA
Nancy Merridew	TAS
Joanna Chua	TAS
Sarah Garner	VIC
Aaron Bloch	VIC
Dorothy Ling	VIC
Arindam Chakravorty	WA

AUSTRALASIAN SOCIETY FOR
INFECTIOUS DISEASES
ABN 20 108 151 093
ACN 155 632 698
PO BOX Q379 QVB SYDNEY 1230
ENQUIRIES@ASID.NET.AU

ASID AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

A COMPANY LIMITED BY GUARANTEE

A.B.N. 20 108 151 093

FINANCIAL REPORT

FOR THE PERIOD ENDED 31 DECEMBER 2022

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD
A.B.N. 20 108 151 093

DIRECTORS' REPORT

Your directors present their report on the company for the period ended 31 December 2022.

DIRECTORS

The names of the directors in office at any time during or since the end of the year are:

A/Prof J Doyle	Prof C Blyth (appointed June 2022)
Prof A Cheng	Dr B McMullan (resigned June 2022)
A/Prof J Clark	Prof K Flanagan
Prof R Stuart	Prof D Paterson

The directors have been in office since the start of the financial period to the date of this report unless otherwise stated.

OPERATING RESULTS

The company produced a net profit (loss) for the financial year amounting to (loss $34,084) (2021 loss: $25,935).

REVIEW OF OPERATIONS

A review of the operations of the company during the financial year and the results of those operations are as follows:

- The principal activity of the company during the financial year was to cultivate and promote interest and support in the field of medicine for infectious diseases.
- No significant change in the nature of these activities occurred during the financial year.
- The company was incorporated on 14 September 2018 to take over the operations of the Australasian Society for Infectious Diseases Inc.

MISSION/PURPOSE

The Society is a charitable institution that exists to provide a range of services and support for promoting the treatment and control of infectious diseases and medical conditions, disorders and ailments arising directly from infectious diseases and the consequent impact that infectious disease can have on human health generally, on specific diseases, on public safety, productivity and quality of life generally.

GOALS

Promoting and advancing knowledge and education in all areas of the science and clinical practice of the fields of infectious diseases, clinical microbiology and associated syndromes and ailments;

Convening regular scientific meetings and arranging other research and educational seminars and conferences on infection-related topics in the Australasian region including topics covering the affairs, interest and duties of members of the medical and related health professions and others engaged in the practice, study and control of infectious diseases;

Encouraging and facilitating clinical and laboratory research in the field of infectious diseases;

Awarding research grants from the funds of the Society and establishing scholarships, prizes or awards in such manner as the Board may determine

Engaging with government, agencies and departments to guide and support policy development for the management and control of infectious diseases and antimicrobial resistance;

Facilitating communication between groups and individuals who have an interest in some aspect of infectious disease study, management and control and encouraging professional relationships and understanding of Members.

GOALS (cont'd)

Cooperating with or advising other bodies interested in infectious disease study, treatment, management and control and infectious disease science and communicating with similar organisations in Australia and other parts of the world;

Encouraging public and professional education about the causes and treatment of infectious diseases.

KEY PERFORMANCE MEASURES

The company measures its performance on the basis of sound financial results through prudent management of limited resources and the promotion of research into infectious diseases. The longer term measurement of this success is seen in better patient outcomes for the general public.

EVENTS SUBSEQUENT TO BALANCE DATE

No matters or circumstances have arisen since the end of the financial year which have significantly affected or may significantly affect the operations of the company, the results of those operations, or the state of affairs of the company in future financial years.

LIKELY DEVELOPMENTS

There are no likely developments in the operations of the company, which are expected to affect the results of the company's operations in subsequent financial years.

ENVIRONMENTAL ISSUES

The company's operations are not regulated by any significant environmental regulation under a law of the Commonwealth or of a State or Territory.

DIVIDENDS

The company is limited by guarantee and the Constitution does not permit the distribution of dividends to its members.

No dividends have been paid, declared or proposed by the company since the commencement of the financial year.

DIRECTORS' BENEFITS

Since the commencement of the financial year no director of the company has received or become entitled to receive, a benefit because of a contract that the director, a firm of which the director is a member, or an entity in which the director has a substantial financial interest, has made with:

- The company, or
- An entity that the company controlled or a body corporate that was related to the company, when the contract was made or when the director received, or became entitled to receive, the benefit.

OPTIONS

The company does not have a share capital as it is a company limited by guarantee. Accordingly, no options over interests in the company were granted during or since the end of the financial year and there were no options outstanding at the date of this report.

INSURANCE OF OFFICERS

During the financial year, the Company did not pay a premium to insure certain officers of the company.

PROCEEDINGS ON BEHALF OF THE COMPANY

No person has applied for leave of Court to bring proceedings on behalf of the company or intervene in any proceedings to which the company is party for the purpose of taking responsibility on behalf of the company for all or any part of those proceedings.

The company was not a party to any such proceedings during the year.

DIRECTORS MEETINGS

During the period 31 December 2022, seven (7) meetings of the company's directors was held.

For each director, particulars of the relevant numbers of meetings held and attended during the period of directorship are shown below:

Director	Meetings Eligible To Attend	Meetings Attended
	Executive	Executive
Dr C Blyth	3	3
Prof A Cheng	7	7
A/Prof J Doyle	7	7
Prof K Flanagan	7	7
Dr B McMullan	6	6
A/Prof J Clark	7	7
Prof R Stuart	7	4
Prof D Paterson	7	6

DIRECTORS QUALIFICATIONS

Particulars of the directors' experience and special responsibilities (if any) of each director of the company who held office during or since the end of the financial year are:

DIRECTOR	RESPONSIBILITIES / EXPERIENCE
Prof Christopher Blyth	Practising physician in Perth. Professor at School of Medicine University of Western Australia and Director of Wesfarmers Centre for Infectious Diseases FRACP,FRCPA, PhD. In June 2022 elected to the Council of the Australasian Society for Infectious Diseases Inc to the position of Councillor.
Prof Allen Cheng	Practicing physician (Alfred Health) MBBS (1993), FRACP (2002) PhD (2005), MPH (2007), MBiostat (2014), GAICD (2017) In May 2018 elected to the Council of the Australasian Society for Infectious Diseases Inc to the position of President from June 2020 to June 2022. On Council since 2013.
Dr Joseph Doyle	Practising consultant in Melbourne, MBBS 2002, MPH 2006, FRACP 2011, FAFPHM 2014, PhD 2015. Elected to Council of ASID in April 2016, Deputy Chair of Viral Hepatitis Special Interest Group in March 2017, and Chair of Finance Committee in August 2018.
Dr Brendan McMullan	Practising consultant (Sydney Children's Hospital); FRACP 2012; FRCPA 2012; BMed(Hons) 2001. (Elected to Council in May 2018). Appointed Honorary Secretary in June 2021. Resigned June 2022.

DIRECTORS QUALIFICATIONS (cont'd)

Prof Katie Flanagan	Practising consultant (Launceston General Hospital, Tasmania) MBBS (1992) DTM&H (1994) PhD (2000) CCST (2004) FRCP(UK) (2009) FRACP (2013). In 2017 elected to the Council of the Australasian Society for Infectious Diseases Inc to the position of Honorary Secretary until June 2021. Elected President in June 2022. On Council since 2013.
A/Prof Julia Clark	Director of Infectious diseases/Immunology/Rheumatology at Queensland Children's Hospital. On various ASID committees since 2012. Her clinical experience encompasses Infectious Disease/Immunology training and consultant experience in the UK, from developing and delivering national ID training programmes to leading and managing an Infection Management Service in Queensland.
Prof Rhonda Stuart	Medical Director of Infection Prevention and Epidemiology at Monash Health and Director of South East Local Public Health Unit . She is an ID Physician and a Professor at Monash University. She is a member of the National Prescribing Service Antimicrobial Resistance Reference Group.
Prof David Paterson	Director of the University of Queensland Centre for Clinical Research. An ID Physician and author of over 490 peer-reviewed publications and is ranked in the top 10 worldwide in the field of microbial drug resistance. He has been a Clarivate Highly Cited Researcher annually from 2015 to 2020.

The company is registered with the Australian Securities and Investments Commission as well as the Australian Charities and Not-for-profit Commission and is a company limited by guarantee. If the company is wound up, the constitution states that each member is required to contribute a maximum of $1.00 each towards meeting any outstanding obligations of the entity. At 31 December 2022, the total amount that members of the company are liable to contribute if the company is wound up is $1,196.00

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out on page 7.

Signed in accordance with a resolution of the Board of Directors:

Director: Katie L Flanagan

Dated this 4th day of April 2023

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

A.B.N. 20 108 151 093

AUDITOR'S INDEPENDENCE DECLARATION
UNDER SECTION 60-40C OF AUSTRALIAN CHARITIES AND NOT-FOR PROFIT COMMISSION ACT 2012

In accordance with Subdivision 60-C of the Australian Charities and Not-for-profit Commission Act 2012, I am pleased to provide the following declaration of independence to the directors of Australasian Society for Infectious Diseases Ltd.

I declare that, to the best of my knowledge and belief, during the period ended 31 December 2022 there has been:

(i) no contraventions of the auditor's independence requirements as set out in the Australian Charities and Not-for-profit Commission Act 2012 in relation to the audit; and

(ii) no contraventions of any applicable code of professional conduct in relation to the audit.

MARK TINWORTH
CHARTERED ACCOUNTANT

North Sydney, April 2023

INDEPENDENT AUDIT REPORT
TO THE MEMBERS OF AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

Opinion

We have audited the attached financial report of Australasian Society for Infectious Diseases Ltd ("the entity") which comprises the statement of financial position as at 31 December 2022, the statement of profit or loss and other comprehensive income, statement of recognised income and expenditure, cash flow statement for the period then ended, and notes to the financial statements, including a summary of significant accounting policies, other explanatory notes and the Directors' Report.

In our opinion, the accompanying financial report of Australasian Society for Infectious Diseases Ltd is in accordance with Division 60 of the Australian Charities and Not-for-profit Commission Act 2012, including:

1. giving a true and fair view of the Company's financial position as at 31 December 2022 and of its financial performance for the period then ended; and

2. complying with Australian Accounting Standards, and Division 60 of the Australian Charities and Not-for-profit Commission Act 2012 (ACNC Act 2012).

Basis for Opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Report* section of our report. We are independent of the Directors in accordance with the auditor independence requirements of the ACNC Act 2012 and the ethical requirements of the Accounting Professional and Ethical Standard Board's APES 110: *Code of Ethics for Professional Accountants* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis of our opinion.

Responsibilities of the Directors for the financial report

The directors are responsible for the preparation and fair presentation of the financial report that gives a true and fair view and have determined the basis of preparation described in Note 1 to the financial report is appropriate to meet the requirements of the ACNC Act and is appropriate to meet the needs of the members. The directors' responsibility also includes such internal control as the directors determine is necessary to enable the preparation of a financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's responsibility

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

- Identify and assess the risks of material misstatements of the financial report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis of our opinion. The risk of not detecting material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, international omissions, misrepresentations, or the override of internal control

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Committee's internal control

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.

- Conclude on the appropriateness of the company's use of going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial report or, if such disclosures are inadequate, to modify our opinion.

- Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial report, including the disclosures, and whether the financial report represents the underlying transactions and events in a manner that achieved fair representation.

We communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

MARK TINWORTH
CHARTERED ACCOUNTANT

North Sydney April 2023

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

A.B.N. 20 108 151 093

DIRECTORS' DECLARATION

The directors of the company declare that:

1. The financial statements and notes, as set out on pages 10 to 26 are in accordance with the requirements of the Australian Charities and Not-for-profit Commission Act 2012 and:

   (a) comply with Australian Accounting Standards applicable to the entity; and

   (b) give a true and fair view of the company's financial position as at 31 December 2022 and of its performance for the period ended on that date of the company.

2. In the directors' opinion there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

This declaration is signed in accordance with subs 60.15(2) of the Australian Charities and Not-for-profit Commission Regulation 2013.

Director: Katie L Flanagan

Dated this 4th day of April 2023

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

A.B.N. 20 108 151 093

STATEMENT OF COMPREHENSIVE INCOME
FOR THE PERIOD ENDED 31 DECEMBER 2022

	Note	2022 $	2021 $
Revenues	2	691,290	478,937
Employee benefits expense		(256,051)	(267,584)
Depreciation expenses		(2,671)	(1,441)
Conference expenses		(357,321)	(69,276)
Special interest group expenses		(19,280)	(58,819)
Administration expenses		(90,051)	(107,752)
Profit (loss) before income tax	3	(34,084)	(25,935)
Income tax expense	1	-	-
Profit after income tax		(34,084)	(25,935)
Other comprehensive income after income tax		-	-
Total comprehensive income for the year		-	-
Total comprehensive income attributable to members of the entity		(34,084)	(25,935)

The accompanying notes form part of these financial statements

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

A.B.N. 20 108 151 093

STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2022

	Note	2022	2021
		$	$
CURRENT ASSETS			
Cash and cash equivalents	4	1,912,914	2,135,358
Other assets	5	100,524	20,673
TOTAL CURRENT ASSETS		2,013,438	2,156,031
NON-CURRENT ASSETS			
Property, plant and equipment	6	61,058	9,239
TOTAL NON-CURRENT ASSETS		61,058	9,239
TOTAL ASSETS		2,074,496	2,165,270
CURRENT LIABILITIES			
Trade and other payables	7	31,862	81,190
Short term provisions	8	18,472	25,834
TOTAL CURRENT LIABILITIES		50,334	107,024
TOTAL LIABILITIES		50,334	107,024
NET ASSETS		2,024,162	2,058,246
EQUITY			
Retained Earnings		2,024,162	2,058,246
TOTAL EQUITY		2,024,162	2,058,246

The accompanying notes form part of these financial statements

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

A.B.N. 20 108 151 093

STATEMENT OF RECOGNISED INCOME AND EXPENDITURE FOR THE PERIOD ENDED 31 DECEMBER 2022

	Retained Earnings
	$
Balance 1 January 2021	2,058,246
Profit (Loss) for the 2022 year	(34,084)
Balance as at 31 December 2022	2,024,162

The accompanying notes form part of these financial statements.

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

A.B.N. 20 108 151 093

STATEMENT OF CASH FLOWS
FOR THE PERIOD ENDED 31 DECEMBER 2022

	Note	2022 $	2021 $
CASH FLOWS FROM OPERATING ACTIVITIES			
Members' & Customers' Receipts		669,457	476,457
Interest Received		11,832	3,204
Payments to Suppliers & Donations		(849,243)	(412,085)
Net Cash Generated from Operating Activities	11	(167,954)	67,576
Cash Flows From Investing Activities			
Purchase of plant		(54,490)	(8,863)
Net Cash Generated from Investing Activities		(54,490)	(8,863)
Net Increase (Decrease) in Cash Held		(222,444)	58,713
Cash at the Beginning of The Financial Year		2,135,358	2,076,645
Cash at the End of the Financial Year	4	1,912,914	2,135,358

The accompanying notes form part of these financial statements.

1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

This financial report covers the Australasian Society for Infectious Diseases Ltd as an individual entity. The Australasian Society for Infectious Diseases Ltd is a company limited by guarantee.

The financial statements were authorised for issue on March 2023.

Basis of preparation

The financial report is a general purpose financial report that has been prepared in accordance with Australian Accounting Standards (including Australian Accounting Interpretations) and the Australian Charities and Not-for-profit Commission Act 2012. The company is a not-for-profit entity for financial reporting purposes under Australian Accounting Standards. Material accounting policies adopted in the preparation of this financial report are presented below and have been consistently applied unless otherwise stated.

The financial statements, except for the cash flow information, have been prepared on an accruals basis and are based on historic costs, modified, where applicable by the measurement at fair value of selected non-current assets, financial assets and financial liabilities. The amounts presented in the financial statements have been rounded to the nearest dollar.

Income Tax

No provision for income tax has been raised as the entity is exempt from income tax under Division 50 of the Income Tax Assessment Act 1997.

Financial Instruments

Initial recognition and measurement

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions to the instrument. For financial assets, this is the date that the Company commits itself to either the purchase or sale of an asset.

Financial instruments (except for trade receivables) are initially measured at fair value plus transaction costs, except where the instrument is classified "at fair value through profit or loss", in which case the transaction costs are expensed to profit or loss immediately. Where available, quoted prices in an active market are used to determine fair value. In other circumstances, valuation techniques are adopted.

Trade receivables are initially measured at the transaction price if the trade receivable do not contain a significant financing component or if the practical expedient was applied as specified in AASB 15.63.

Classification and subsequent measurement

Financial liabilities

Financial liabilities are subsequently measured at:

- Amortised cost, or
- Fair value through profit and loss

A financial liability is measured at fair value through profit and loss if the financial liability is:
- A contingent consideration of an acquirer in a business combination to which AASB 3 applies
- Held for trading, or
- Initially designated as at fair value through profit and loss

1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

Financial liabilities (cont'd)

All other financial liabilities are subsequently measured at fair value, amortised cost using the effective interest rate. The effective interest rate method is a method of calculating the amortised cost of a debt instrument and of allocating interest expense in profit or loss over the relevant period.

The effective interest rate is the internal rate of return of the financial asset or liability. That is, it is the rate that exactly discounts the estimated future cash flows through the expected life of the instrument to the net carrying amount at initial recognition.

Financial asset

Financial assets are subsequently measured at:

- Amortised cost
- Fair value through other comprehensive income
- Fair value through profit and loss

Measurement is on the basis of the two primary criteria:

- the contractual cash flow characteristics of the financial asset, and
- the business model for managing the financial assets

A financial asset is subsequently measured at amortised cost when it meets the following conditions:

- the financial asset is managed solely to collect contractual cash flows; and
- the contractual terms within the financial asset give rise to cash flows that are solely payments of principal and interest on the principal amount outstanding on specified dates.

A financial asset is subsequently measured at fair value though other comprehensive income when it meets the following conditions:

- the contractual terms within the financial asset give rise to cash flows that are solely payments of principal and interest on the principal amount outstanding on specified dates: and
- the business model for managing the financial asset comprises both contractual cash flows collection and the selling of the financial asset.

By default, all other financial assets that do not meet the conditions of amortised cost and fair value through other comprehensive income's measurement condition are subsequently measured at fair value through profit and loss.

The entity initially designates financial instruments as measured at fair value through profit and loss if:

- it eliminates or significantly reduces a measurement or recognition inconsistency that would otherwise arise from measuring assets or liabilities or recognizing the gains and losses on them on different bases.
- It is in accordance to the documented risk management or investment strategy and information about the groupings was documented appropriately, so the performance of the financial liability that was part of the entity of financial liabilities or financial assets can be managed and evaluated consistently on a fair value basis; and
- It is a hybrid contract that contains an embedded derivative that significantly modifies the cash flows otherwise required by the contract.

Derecognition

Derecognition refers to the removal of a previously recognised financial assert or financial liability from the statement of financial position.

1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

Derecognition (cont'd)

Derecognition of financial liabilities:

A liability is derecognised when it is extinguished. An exchange of an existing financial liability for a new one with substantial modified terms, or a substantial modification to the terms of a financial liability, is treated as an extinguishment of the existing liability and recognition of a new financial liability.

The difference between the carrying amount of the financial liability derecognized and the consideration paid and payable, including any non-cash assets transferred or liabilities assumed, is recognised in profit or loss.

Derecognition of financial assets:

A financial asset is derecognised when the holder's contractual rights to its cash flows expires, or the asset is transferred in such a way that all the risks and rewards of ownership are substantially transferred.

All of the following criteria need to be satisfied for derecognition of financial asset:

- The right to receive cash flows from the asset has expired or been transferred;
- All risk and rewards of ownership of the asset have been substantially transferred; and
- The entity no longer controls the asset

On derecognition of a financial asset measured at amortised cost, the difference between the asset's carrying amount and the sum of the consideration received and receivable is recognised in the profit or loss.

Impairment
The company recognises a loss allowance for expected credit losses on financial assets that are measured at amortised cost or fair value through other comprehensive income.

Loss allowance is not recognised for financial assets measured at fair value through profit or loss.

Expected credit losses are the probability-weighted estimate of credit losses over the expected life of a financial instrument. A credit loss is the difference between all contractual cash flows that are due and all cash flows expected to be received, all discounted at the original effective interest rate of the financial instrument.

General approach

Under the general approach, at each reporting period, the company assesses whether the financial instruments are credit-impaired, and:

- If the credit risk of the financial instrument has increased significantly since initial recognition, the Entity measures the loss allowance of the financial instruments at an amount equal to the lifetime expected credit losses; and

- If there has been no significant increase in credit risk since initial recognition, the Entity measures the loss allowance for that financial instrument at an amount equal to 12-month expected credit losses.

Recognition of expected credit losses in financial statements

At each reporting date, the company recognise the movement in the loss allowance as an impairment gain or loss in the statement of profit or loss and other comprehensive income.

The carrying amount of financial assets measured at amortised cost includes the loss allowance relating to that asset.

1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

Impairment (cont'd)
Assets measured at fair value through other comprehensive income are recognised at fair value with changes in fair value recognised in other comprehensive income. The amount in relation to change in credit risk is transferred from other comprehensive income to profit or loss at every reporting period.

Impairment of Assets

At each reporting date, the Company reviews the carrying values of it tangible and intangible assets to determine whether there is any indication that those assets have been impaired. If such an indication exists, the recoverable amount of the asset, being the higher of the assets fair value less cost to sell and value in use, is compared to the asset's carrying value. Any excess of the asset's carrying value over its recoverable amount is recognised in profit or loss.

Where the assets are not held primarily for their liability to generate net cash inflows – that is, they are specialised assets held for continuing use of their service capacity – the recoverable amounts are expected to be materially the same as fair value.

Where it is not possible to estimate the recoverable amount of an individual asset, the entity estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Where an impairment loss on a revalued individual asset is identified, this is recognised against the revaluation surplus in respect of the same class of asset to the extent that the impairment loss does not exceed the amount in the revaluation surplus for that class of asset.

Depreciation of Plant and Equipment
Each class of property plant and equipment is carried at cost or fair value less, where applicable, any accumulated depreciation.

Plant and equipment are measured on the cost basis. All assets are depreciated using the straight line basis so as to write off the cost of each asset over its expected useful life to the company.

Depreciation rates used for each class of asset are:

Class of fixed asset	Depreciation rate
Plant and Equipment	10.0%
Fixtures and Fittings	12.5%

An asset carrying amount is written down immediately to its recoverable amount if the assets carrying amount is greater than its estimated recoverable amount.

Gains and losses on disposal are determined by comparing proceeds with the carrying amount. These gains and losses are included in the statement of comprehensive income. When revalued assets are sold, amounts included in the revaluation reserve relating to that asset are transferred to retained earnings.

Lease payments are allocated between the reduction of the lease liability and the lease interest expense for the period.

Lease payments for leases not classified as finance leases under AASB 16 – Leases, are charged as expenses on a straight-line basis over the lease term.

Revenue
Membership revenue is measured at the fair value of the consideration received and is brought to account on receipts basis.

1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

Revenue (cont'd)
Interest revenue is recognised proportionally using the effective interest rate method, which for floating rate financial assets is the rate inherent in the instrument.

Grant revenue is recognised in the statement of comprehensive income when the entity obtains control of the grant and it is probable that the economic benefits gained from the grant will flow to the entity and the amount of the grant can be measured reliably.If conditions are attached to the grant which must be satisfied before it is eligible to receive the contribution, the recognition of the grant as revenue will be deferred until those conditions are satisfied.

When grant revenue is received whereby the entity incurs an obligation to deliver economic value directly back to the contributor, this is considered to be a reciprocal transaction and the grant revenue is recognised in the statement of financial position as a liability until the service has been delivered to the contributor, otherwise the grant is recognised as revenue on receipt.

Revenue from the rendering of a service is recognised upon delivery of the service to the customer.

All revenue is stated net of the amount of Goods and Service Tax ("GST").

Goods and Services Tax
Revenues, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the ATO.

Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the ATO is included with other receivables or payables in the statement of financial position.Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities, which are recoverable from or payable to the ATO, are presented as operating cash flows included in receipts from customers or payments to suppliers.

Trade and other payables
Trade and other payables represent the liability outstanding at the end of the reporting period for goods and services received by the company during the reporting period which remain unpaid. The balance is recognised as a current liability with the amounts normally paid within 30 days of recognition of the liability.

Employee Entitlements
Provision is made for the liability for employee entitlements arising from services rendered by employees to balance date. Employee entitlements expected to be settled within one year together with entitlements arising from wages and salaries and annual leave which will be settled after one year have been measured at their nominal amount. Other employee entitlements payable later than one year have been measured at the present value of the estimated future cash outflows to be made for those entitlements. Contributions are made to an employee superannuation fund and are charged as expenses when incurred. The company has no legal obligation to provide benefits to employees on retirement.

Cash and Cash equivalents
For the purpose of the statement of cash flows, cash includes cash on hand and at call deposits with banks or financial institutions, net of bank overdrafts

Critical Accounting Estimates and Judgments
The directors evaluate estimates and judgments incorporated into the financial report based on historical knowledge and best available current information. Estimates assume a reasonable expectation of future events and are based on current trends and economic data, obtained both externally and within the company.

1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

Key judgements
Performance obligations under AASB 15

To identify a performance obligation under AASB 15, the promise must be sufficiently specific to be able to determine when the obligation is satisfied. Management exercises judgement to determine whether the promise is sufficiently specific by taking into account any conditions specific in the arrangement, explicit or implicit, regarding the promised goods or services. In making this assessment, management includes the nature/type, cost/value. Quantity and the period of transfer related to the goods or services promised.

Comparative figures
When required by accounting standards, comparative figures have been adjusted to conform to changes in presentation for the current year.

Liability of Members'
The company is limited by guarantee. If the company is wound up, Clause 9 of the Constitution states that in the event of there being a deficiency of net assets on winding up, each member and members within one year of ceasing to be members undertake to contribute a sum not exceeding one dollar per person. As at 31 December 2022 the number of members was 1,196

New and Amended Accounting Policies Adopted by the Company

Initial adoption of AASB 2018-6: *Amendments to Australian Accounting Standards – Definition of a Business*

- AASB: 2018-7: Amendments to Australian Accounting Standards – Definition of Material

This amendment principally amends AASB 101 and AASB 1008 by refining the definition of material by improving the wording and aligning the definition across the standards issues by the AASB.

New and Amended Accounting Policies Adopted by the Company

AASB 106: *General Purpose Financial Statements – Simplified Disclosures for For-Profit and Not-for-Profit Tier 2 Entities*

- The AASB has issues AASB 1060: *General Purpose Financial Statements – Simplified Disclosures for For-Profit and Not-for-Profit Tier 2 Entities*. AASB 1060 defines the disclosure requirements for Tier 2 general purpose financial statements, as defined by Australian Accounting Standards, and serves as a replacement for the existing Reduced Disclosure Regime.

AASB 1060 may be early-adopted and is mandatory for periods beginning on or after 1 July 2021 (and is mandatory for the Company's 31 December 2022 year-end).

	2022 $	2021 $

2. Revenue

	2022 $	2021 $
Operating Activities		
Membership Subscriptions	119,337	204,574
Conference Income	553,799	251,657
Special interest group income	-	11,232
Sponsorship	-	5,000
Foreign exchange gain	5,922	3,214
Sale of publications/advertising	400	56
Interest Received	11,832	3,204
	691,290	478,937

3. Profit (Loss) from Ordinary Activities

Profit (Loss) from ordinary activities before income tax has been determined after:

	2022 $	2021 $
(a) Expenses:		
Auditor's remuneration:		
- Audit	4,473	4,942
Depreciation of plant and equipment	2,671	1,441
Employee leave provisions	(7,365)	1,629

4. Cash and cash equivalents

	2022 $	2021 $
Cash at Bank – Cheque Account	1,711,959	538,907
Cash at Bank – Term Deposits	200,955	1,596,451
	1,912,914	2,135,358

The effective interest rate on short term deposits was 0.58% and these deposits have an average maturity of ninety two days.

5. Other Current Assets

	2022 $	2021 $
Current		
Prepaid Expenses	90,524	20,673
Other Debtors	10,000	-
	100,524	20,673

6. Property, plant and equipment

	2022 $	2021 $
Plant and equipment - at cost	92,678	38,188
Less: accumulated depreciation	(31,620)	(28,949)
	61,058	9,239

	2022	2021
	$	$

6. Property, plant and equipment (Cont'd)

Movement in carrying amounts

Movement in carrying amounts for each class or plant and equipment between the beginning and end of the current financial year

	2022	2021
Balance at the beginning of the year	9,239	1,817
Additions	54,490	8,863
Depreciation expense	(2,671)	(1,441)
Carrying amount at end of year	61,058	9,239

7. Trade and other payables

	2022	2021
Current		
Trade Creditors & Accruals	31,862	81,190
	31,862	81,190

8. Provisions

	2022	2021
Current		
Annual Leave Entitlements	18,742	25,834
Number of employees at year end	4	4

9. Related party transactions

No Director member receives directly or indirectly any fees, bonuses or other remuneration as a consequence of their appointment to the Board.

10. Financial instruments

Financial risk management

The Company's financial instruments consist mainly of deposits with banks, local money market instruments and short-term investments, accounts receivable and payable.

The Company does not have any derivative financial instruments at 31 December 2022.

Financial Risk Management Policies

The Director's overall risk management strategy seeks to assist the Company in meeting its financial targets, whilst minimising potential adverse effects on financial performance. Risk management policies are approved and reviewed by the Directors' on a regular basis.

The totals for each category of financial instruments, measured in accordance with AASB 9 is detailed in the accounting policies to these financial statements, are as follows:

10. Financial instruments (Cont'd)

	2022 $	2021 $
Financial assets		
Cash & cash equivalents	1,912,914	2,135,358
Trade & other receivables	10,000	-
	1,922,914	2,135,358
Financial liabilities		
Trade & other payables	31,882	81,190
Less Deferred revenue	-	-
Less GST payable	(8,634)	(12,688)
Financial liabilities	23,248	68,502

i. Treasury risk management
A finance committee consisting of senior Board members meet on a regular basis to analyse currency and interest rate exposure and to evaluate treasury management strategies in the context of the most recent economic conditions and forecasts.

ii. Financial risks
The main risks the Company is exposed to through its financial instruments are interest rate risk, liquidity risk and credit risk.

Interest rate risk
All financial assets and liabilities are non-interest bearing except for the following:
Cash assets at an average interest rate for the year of 0.58%

Foreign currency risk
The Company is not exposed to fluctuations in foreign currencies

Interest rate risk
The Company's exposure to interest rate risk, which is the risk that a financial instrument's value will fluctuate as a result of changes in market interest rates and will affect future cash flows or the fair value of fixed rate financial instruments.

Floating rate instruments

Cash & cash equivalents	1,912,914	2,135,358

Liquidity risk
Liquidity risk arises from the possibility that the Company might encounter difficulty in settling its debts or otherwise meeting its obligations related to financial liabilities

The Company manages this risk through the following mechanisms:

- preparing forward-looking cash flow analysis in relation to its operational, investing and financing activities;
- obtaining funding from various sources
- maintaining a reputable credit profile
- managing credit risk related to financial assets
- only investing surplus cash with major financial institutions
- comparing the maturity profile of financial liabilities with the realisation profile of financial assets.

10. Financial instruments (Cont'd)

Financial liability and financial asset maturity analysis

	2022 $	2021 $
	Within one year	
Financial liabilities due for payment:		
Trade & other payables excluding deferred income and GST payable	23,248	68,502
Total expected outflows	23,248	68,502
Financial assets – cash flows realisable:		
Cash & cash equivalents	1,912,914	2,135,358
Trade & other receivables	10,000	-
Total anticipated inflows	1,922,914	2,135,358
Net (outflows) inflows on financial instruments	1,899,666	2,066,856

Foreign exchange risk
The Company is exposed to fluctuations in foreign currencies due to the New Zealand denominated account held during the period.

Credit risk
Exposure to credit risk relating to financial assets arises from the potential non-performance by counterparties of contractual obligations that could lead to a financial loss to the Company. Credit risk is managed through maintaining procedures ensuring, to the extent possible, that customers and counterparties to transactions are of sound credit worthiness and includes utilisation of systems for that approval, granting and renewal of credit limits, the regular monitoring of exposures against such limits and the monitoring of the financial stability of significant customers and counterparties. Such monitoring is used in assessing receivables for impairment. Credit terms are normally 14-30 days from the date of invoice.

Customers that do not meet the Company's strict credit policies may only purchase in cash or using recognised credit cards.

Risk is also minimised through investing surplus funds in financial institutions that maintain high credit ratings or in entities that the finance committee has otherwise cleared as being financially sound.

The maximum exposure to credit risk by class of recognised financial assets at balance date, excluding the value of any collateral or other security held, is equivalent to the carrying value and classification of those financial assets (net of any provisions) as presented in the balance sheet.

The company has no significant concentration of credit risk with any single counterparty or group of counterparties.

Trade & other receivables that are neither past due or impaired are considered to be of high credit quality aggregates of such amounts are as detailed in Note 5

The Company does not have any material credit risk exposure to any single receivable or group of receivables under financial instruments entered in to by the Company.

Credit risk related to balances with banks and other financial institutions is managed by the finance committee in accordance with approved Committee policy. The following table provides information regarding the credit risk relating to cash based on S&P counterparty credit ratings.

10. Financial instruments (Cont'd)

Cash and cash equivalents

	2022 $	2021 $
- A+ rated	-	715,526
- AA- rated	1,912,914	1,419,832

Price risk
The company is not exposed to any material commodity price risk.

Net fair values

Fair value estimation
The fair values of financial assets and financial liabilities are presented in the following table and can be compared to their carrying values as presented in the balance sheet. Fair values are those amounts at which an asset could be exchanged, or a liability settled, between knowledgeable, willing parties in an arms-length transaction. Fair values derived may be based on information that is estimated or subject to judgement, where changes in assumptions may have a material impact on the amounts estimated, Areas of judgement and the assumptions have been detailed below.

Differences between fair values and carrying values of financial instruments with fixed interest rates are due to the change in discount rates being applied by the market since their initial recognition by the company.

	2022		2021	
	Net carrying value	Net fair value	Net carrying value	Net fair value
Financial assets				
Cash & cash equivalents	1,912,914	1,912,914	2,135,358	2,135,358
Trade & other receivables	10,000	10,000	-	-
Total financial assets	1,922,914	1,922,914	2,135,358	2,135,358
Financial Liabilities				
Trade & other payables	23,248	23,248	68,502	68,502
Total financial liabilities	23,248	23,248	68,502	68,502

The fair values of these financial assets have been based on the closing quoted bid prices at the end of the reporting period, excluding transaction costs.

The fair values disclosed in the above table have been determined based on the following methodologies:

(i) Cash and cash equivalents, trade and other receivables and trade and other payables are short term instruments in nature whose carrying value is equivalent to fair value.

Sensitivity analysis
The following table illustrates sensitivities to the company's exposures to changes in interest rates and equity prices. The table indicates the impact on how profit and equity values reporting at the end of the reporting period would have been affected by changes in the relevant risk variable that management considers to be reasonably possible. These sensitivities assume that the movement in a particular variable is independent of other variables.

	2022	2021
	$	$

10. Financial instruments (Cont'd)

	Profit	Equity
Year ended 31 December 2022	**$**	**$**
+/- 2% in interest rates	40,343	40,343

No sensitivity analysis has been performed on foreign exchange risk as it is not considered to be material to the company.

11. Cash Flow Information

(a) Reconciliation of net cash provided by operating activities to profit (loss) from ordinary activities after income tax

	2022	2021
Operating Profit (Loss) after Income Tax	(34,084)	(29,935)
Non-Cash Flows in Operating Profit:		
- Depreciation	2,671	1,441
Changes in Assets and Liabilities:		
- (Increase) Decrease in Other Assets	(79,852)	66,115
- Increase (Decrease) in Payables	(49,327)	24,326
- Increase (Decrease) in Provisions	(7,362)	1,629
Net Cash (used in) provided by Operating Activities	(167,954)	67,576

(b) The company has no credit stand-by or financing facilities in place.
(c) There were no non-cash financing or investing activities during the year.

12. Contingent Liabilities and Contingent Assets

The company is not aware of any contingent liabilities that are in existence at the date of the signing of this report.

13. Events after the Balance Sheet Date

The Covid 19 pandemic has been significantly affecting the financial environment. There is a possibility that it will significantly affect the operations of the Society, the results of these operations or the state of affairs of the Society in future financial years.

As at the date of this report, it is not possible to reliably estimate the financial effect (if any) of the virus on the Society's operations.

Apart from the effect of Covid 19, there has not arisen in the interval between the end of the financial year and the date of this report any item, transaction or event of a material or unusual nature, which in the opinion of the Director's will affect significantly the operations of the company, the results of these operations or the state of affairs of company in future financial years.

14. Company Details

The principal place of business of the company is:
Australasian Society for Infectious Diseases Ltd
145 Macquarie Street
SYDNEY NSW 2000

The company's registered office is:
Australasian Society for Infectious Diseases Ltd
145 Macquarie Street
SYDNEY NSW 2000

TINWORTH & Co
CHARTERED ACCOUNTANTS and BUSINESS ADVISORS

COMPILATION REPORT

TO AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

On the basis of information provided by the directors of the Australasian Society for Infectious Diseases Ltd, we have compiled in accordance with APES 315: 'Statement on Compilation of Financial Reports', the special purpose financial report of the Australasian Society for Infectious Diseases Ltd for the period ended 31st December 2022, as set out in the attached Detailed Profit and Loss Statement.

The specific purpose for which the special purpose financial report has been prepared is to provide private information to the directors. The extent to which Accounting Standards and other mandatory professional reporting requirements have or have not been adopted in the preparation of the special purpose financial report set out in Note 1.

The directors are solely responsible for the information contained in the special purpose financial report and have determined that the accounting policies used are and are appropriate to satisfy the requirements of the directors.

Our procedures use accounting expertise to collect, classify and summarise the financial information, which the directors provided, into a financial report. Our procedures do not include verification or validation procedures. No audit or review has been performed and accordingly no assurance is expressed.

To the extent permitted by law, we do not accept liability for any loss or damage which any person, other than the company, may suffer arising from any negligence on our part. No person should rely on the special purpose financial report without having an audit or review conducted.

The special purpose financial report was prepared for the benefit of the company and its members and the purpose identified above. We do not accept responsibility to any other person for the contents of the special purpose financial report.

MARK TINWORTH
CHARTERED ACCOUNTANT

North Sydney, April 2023

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD
A.B.N. 20 108 151 093

PRIVATE INFORMATION FOR THE DIRECTORS
ON THE 2022 FINANCIAL STATEMENTS

CONSOLIDATED PROFIT AND LOSS STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2022

	2022	2021
INCOME	**$**	**$**
Membership income	119,337	207,788
Conference income	553,799	251,657
Sponsorship	-	5,000
ZOOSIG income	-	11,232
Interest received	11,832	3,204
Sundry income	6,322	56
	691,290	478,937
EXPENDITURE		
Audit fees	4,473	4,942
Accountancy fees	4,893	5,376
Bank fees	9,961	15,096
Board expenses	625	459
Computer website expenses	18,025	6,906
Conference expenses	357,321	69,276
ANZMIG expenses	10,985	40,736
ANZPID expenses	6,931	-
HICSIG expenses	-	455
Depreciation	2,671	1,441
VACSIG	-	1,000
VHSIG	1,364	909
ZooSig expenses	-	15,719
Insurance	7,504	7,370
Rent	6,807	12,310
Meeting expenses	4,332	5711
Awards & grants	18,654	35,500
Secretariat expenses	14,777	14,082
Secretariat payroll expenses	256,051	267,584
	725,374	504,872
Profit before Income Tax	(34,084)	(25,935)